Quantcast

Latest Artificial heart Stories

2010-10-12 16:41:07

In a Canadian first, the Peter Munk Cardiac Centre used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer lasting than older generation LVADs and may eliminate the need for a second LVAD "“ a major drawback with the old technology. The patient, 61-year-old Marva Lorde of Mississauga, suffered a heart attack in 2007 and underwent several treatments for heart failure "“ including a 10-day intensive care unit...

2010-09-03 17:38:00

FRAMINGHAM, Mass. and SYDNEY Sept. 3 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll a second allotment of 54 patients in its "ADVANCE"...

2010-06-15 01:02:29

Heart failure is a very common condition: around 200,000 people in Sweden have been diagnosed with the disease. Some patients with life-threatening heart failure can be helped by mechanical heart pumps, reveals a thesis from the University of Gothenburg, Sweden. In the thesis, a total of 99 patients with life-threatening heart failure were treated with a heart pump for short- or long-term circulatory support. "Two-thirds of these patients survived," says Hans Lid©n, a researcher at the...

2010-06-14 15:10:00

FRAMINGHAM, Mass. and SYDNEY, June 14 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted HeartWare conditional approval to begin enrollment in an Investigational Device Exemption (IDE) destination therapy clinical study for the...

2010-06-08 12:12:00

WALTHAM, Mass., June 8 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, national registry data presented at last month's euroPCR will drive adoption of transcatheter aortic valve implantation, as illustrated in MRG's new European Markets for Heart Valve Devices 2010 report. Presented by European physicians at the Paris conference, the encouraging registry results revealed high success rates in addition to...

2010-04-23 09:16:00

ADDISON, Texas, April 23 /PRNewswire/ -- New data show improved outcomes, better survival rates and lower costs with the use of continuous flow mechanical circulatory support devices in patients awaiting heart transplants. Research will be presented this week during symposia at the International Society for Heart and Lung Transplantation (ISHLT) 30th Annual Meeting and Scientific Session at the Hilton Chicago. Ventricular Assist Devices (VADs), or heart pumps, are used to partially or...

2010-04-13 07:07:00

WALTHAM, Mass., April 13 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the rigorous FDA approval process is creating major hurdles for percutaneous heart valve device manufacturers. Although percutaneous aortic valves and percutaneous mitral valves gained CE mark approval in Europe in 2007 and 2008, respectively, these devices are not expected to launch in the US market until 2011 and 2012. Percutaneous...

2010-04-07 16:19:00

FRAMINGHAM, Mass. and SYDNEY, April 7 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll up to an additional 54 patients in its "ADVANCE" bridge-to-transplant...

2010-03-12 21:17:00

LOS ANGELES, March 12 /PRNewswire/ -- For patients who are living with a heart problem, the option of surgical treatment can be just as terrifying as their current condition. From aortic aneurysms to Heart Valve Replacement Surgery, Open Heart Surgery is a serious procedure that has definite risks to the patient's health. However, with a great team of talented and experienced cardiothoracic surgeons, patients who need heart valve replacement surgery can go into surgery feeling confident....

2010-02-22 16:15:00

FRAMINGHAM, Mass. and SYDNEY, Feb. 22 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced the conclusion of patient enrollment under its "ADVANCE" clinical trial. HeartWare's ADVANCE clinical trial is an FDA approved IDE study designed to evaluate the HeartWare® Ventricular Assist...


Latest Artificial heart Reference Libraries

0_886104d1c1c698f3a531e056704457d5
2010-10-14 16:46:25

The artificial heart, a mechanical heart replacement, is typically used in order to bridge the time to heart transplant or to replace the heart in case a transplant is impossible. Often ventricular assist devices are confused with mechanical hearts because the assist the heart through pumps. They are also different from a cardiopulmonary bypass machine which is an external device used to provide the function of the heart and lungs. CPBs are usually only used for a few hours at a time,...

More Articles (1 articles) »
Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related